MINDCURE appears to have become the first prominent casualty of the consolidation we expected to see in the psychedelic public markets this year. Below, we take a look at how other companies in the space are faring as cash runways shorten. Elsewhere, secretive biotech Terran Biosciences claims to have over 150 psychedelic-related patents and a new study uses natural language processing to connect…
